- Products (8797)
- Resources (1274)
Cell Signaling Technology Demonstrates the Discovery Capabilities of its PhosphoScan® Proteomics Platform with Identification of Novel Kinase Target in Leukemia
Aug 2006, CST announced the publication of discovery research based on its patent-pending PhosphoScan® proteomics technology, which identified a mutant JAK3 tyrosine kinase as a novel driver in acute myeloid leukemia (AML).
Cell Signaling Technology, Inc. Announces Renewal of PhosphoScan® Proteomics Research Project for Lead Compound Biomarker Discovery
Nov 2008, Renewal of a research agreement with Ortho-Biotech Oncology Research & Development, under which CST will employ its patented PhosphoScan® and PTMScan® technologies in research aimed at biomarker discovery and validation for multiple enzyme target classes and lead small-molecule inhibitors.
CiteAb Names Cell Signaling Technology "Researchers’ Choice" and "PTM Antibody Company of the Year"
Cell Signaling Technology (CST), a leading provider of antibodies, kits, and services, was honored with the 2017 CiteAb Award for &quoPTM Antibody Company of the Year" and for a third year in a row with the award for "Researchers’ Choice."